+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID03191149

Phase II Trial Evaluating Osimertinib for Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Led by National Cancer Institute (NCI) · Updated on 2026-11-03

46

Participants Needed

347

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This trial studies adults with advanced or recurrent non-small cell lung cancer NSCLC that has a specific EGFR exon 20 insertion mutation. It aims to evaluate how well the drug osimertinib works for this condition, focusing on tumor response rates, safety, and survival outcomes. The study also explores molecular markers related to treatment response and resistance. Participants receive oral osimertinib once daily in repeating 21-day cycles, continuing until their disease progresses or side effects become unacceptable. Throughout the trial, participants undergo heart function tests echocardiography or MUGA, imaging scans MRI or CT with contrast, and blood sample collections. After treatment, follow-up visits occur at 30 days and then every three months for up to five years. During the study, researchers monitor tumor response, progression-free survival, overall survival, and any adverse events. Molecular analyses are performed on tumor tissue and circulating tumor DNA to understand treatment effects and resistance. The total participation duration can last up to five years, including treatment and follow-up periods.

CONDITIONS

Brief Title

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here